Nektar Therapeutics
NKTR · NASDAQ
Το Bulios Scoring περιγράφει την ποιότητα και το ιστορικό μιας εταιρείας, όχι τη μελλοντική απόδοση. Ένα υψηλό σκορ δεν είναι σήμα αγοράς. Μάθετε περισσότερα
Σχετικά με την εταιρεία
Nektar Therapeutics (NKTR) is an American biopharmaceutical company focused on researching, developing, and commercializing therapeutic agents for the treatment of cancer and other serious diseases. The company particularly focuses on innovative drugs utilizing its technologies to enhance drug bioavailability and pharmacokinetics. Their research and development efforts are aimed at treating various types of cancer, autoimmune diseases, and painful conditions. Nektar Therapeutics has a broad portfolio of drug candidates in development, both independently and in collaboration with other pharmaceutical companies. With successful approvals and commercialization of its products, Nektar Therapeutics is becoming a significant player in the field of innovative therapeutics. Shares of Nektar Therapeutics (NKTR) could be suitable for investors seeking opportunities in the biopharmaceutical sector with an emphasis on innovation and treatment of serious diseases.
Δεν είναι ακόμη διαθέσιμο στη γλώσσα σας, επομένως το κείμενο είναι στα αγγλικά.
Sector
Healthcare
Industry
Biotechnology
CEO
Howard W. Robin
Employees
63
Headquarters
San Francisco
Επερχόμενα γεγονότα
Earnings
Upcoming earnings report